This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Benefits of technology
[0361] Inasmuch as the compound (I) and a prodrug thereof (hereinafter abbreviated as the compound of the present invention) has a superior MCH receptor antagonistic action, it is useful as an agent for preventing or treating diseases caused by MCH. In addition, the compound of the present invention shows low toxicity, and superior oral absorption performance and transfer into the brain.
[0362] Accordingly, the compound of the present invention is safely administered as an agent for preventing or treating diseases caused by MCH to mammals (e.g., rat, mouse, guinea pig, rabbit, sheep, horse, pig, cow, monkey, human, etc.).
[0383] Examples of the dosage form of a pharmaceutical composition of the present invention include oral preparations such as tablet (inclusive of sugar-coated tablet and firm coated tablet), powder, granule, capsule (inclusive of soft capsule), liquid and the like; parenteral preparations such as injection (e.g., subcutaneous injection, intravenous injection, intramuscular injection, intraperitoneal injection, etc.), external preparation (e.g., transnasal administration preparation, percutaneous preparation, ointment, etc.), suppository (e.g., rectal suppository, pessary, etc.), sustained-release preparation (e.g., sustained-release microcapsule, etc.), pellet, drops and the like; and the like, and can be safely administered orally or parenterally (e.g., topical, rectal, intravenous administration, etc.).
Along with the recent changes in feeding environments, obesity is becoming a social problem.
It is widely known that obesity is not only a serious risk factor of life-style related diseases, such as diabetes, hypertension, arteriosclerosis and the like, but also causes arthritis and pain resulting from an excessive burden on joints of knee etc. due to increased body weight.
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
[0529] To a suspension of N-(3-(formyl-7-quinolinyl)acetamide (5.68 g, 26.5 mmol) in ethanol (60 ml) was added sodiumborohydride (2.01 g, 53.0 mmol) at 0° C., and the mixture was stirred at room temperature for 3 hrs. Ethyl acetate was added to the reaction solution, and the mixture was washed with saturated brine and dried over anhydroussodiumsulfate.
[0530] The solvent was concentrated under reduced pressure and the obtained residue was treated with ethyl acetate to give the title compound (4.47 g) as a powder.
[0533] N-[3-(Hydroxymethyl)-7-quinolinyl]acetamide (4.47 g, 20.7 mmol) obtained in Reference Example 1 was added to thionylchloride (60 ml) at 0° C., and the mixture was stirred at room temperature for 2 hrs. The reaction solution was concentrated under reduced pressure and the obtained residue was treated with isopropylether to give the title compound (5.55 g) as a powder.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Property
Measurement
Unit
Mass
aaaaa
aaaaa
Mass
aaaaa
aaaaa
Mass
aaaaa
aaaaa
Login to view more
Abstract
A compound, which has a melanin-concentrating hormone antagonistic action and useful as an agent for preventing or treating obesity, and which is represented by the formula: wherein Ar is a cyclic group optionally having substituent(s); X is a bond or a spacer having a main chain of 1 to 6 atoms; R1 and R2 are the same or different and each is a hydrogen atom or a hydrocarbon group optionally having substituent(s), or R1 and R2 may form, together with the adjacent nitrogen atom, a nitrogen-containing heterocycle optionally having substituent(s); Y is a divalenthydrocarbon group optionally having substituent(s) (except CO); R3 is a hydrogen atom or a hydrocarbon group optionally having substituent(s); and ring A and ring B may further have substituents, and when ring B further has a substituent, the substituent may be linked to R1 to form a ring, or a salt thereof, or a prodrug thereof, is provided.
Description
TECHNICAL FIELD [0001] The present invention relates to a quinoline compound having a melanin-concentrating hormone (hereinafter sometimes to be abbreviated as MCH) antagonistic action and useful as an agent for preventing or treating obesity and the like. BACKGROUND ART [0002] Feeding behavior is an indispensable action for many organisms including human. An abnormality in feeding behavior causes deviation from normal life support activities, which in most cases results in diseases. Along with the recent changes in feeding environments, obesity is becoming a social problem. It is widely known that obesity is not only a serious risk factor of life-style related diseases, such as diabetes, hypertension, arteriosclerosis and the like, but also causes arthritis and pain resulting from an excessive burden on joints of knee etc. due to increased body weight. In addition, the dieting boom and the like have increased the potential population that desires weight loss. There are many reports...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more